• Region: Europe
  • Sector: Healthcare
  • Investment Year: 2015
  • Transaction Value: €475m

Unrealised

In September 2015, BCEC IX acquired Pharmathen from the founding family. Pharmathen is a leading European pharmaceutical company focused upon developing, manufacturing and out-licensing complex generic drugs.

Pharmathen has a B2B Business Model and focuses on: out-licensing to over 265 customers in over 85 countries; Manufacturing Supply Agreements with minimum 5-year contracts; and a portfolio of 110 own-developed drugs. Additionally, Pharmathen undertakes R&D in Greece with 2 facilities, along with manufacturing at 2 facilities, also in Greece.

The company is headquartered in Amsterdam.

Company News

03 June 2015

BC Partners acquires Pharmathen

Funds advised by BC Partners (“BC Partners”), a leading international private equity firm, have reached an agreement to acquire a majority stake in Pharmathen S.A (“Pharmathen” or “the Company”), a leading European pharmaceutical company. BC Partners will

Read More

Team Involved